1. RODNA
  2. CONICET
  3. CONICET
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.provenanceCONICET-
dc.creatorMcMurray, John J. V.-
dc.creatorAnand, Inder S.-
dc.creatorDiaz, Rafael-
dc.creatorMaggioni, Aldo P.-
dc.creatorO'Connor, Christopher-
dc.creatorPfeffer, Marc A.-
dc.creatorSolomon, Scott D.-
dc.creatorTendera, Micha-
dc.creatorvan Veldhuisen, Dirk J.-
dc.creatorMoetaz, Albizem-
dc.creatorCheng, Sunfa-
dc.creatorScarlata, Debra-
dc.creatorSwedberg, Karl-
dc.creatorYoung, James B.-
dc.creatorToblli, Jorge Eduardo-
dc.creatorRED-HF Committees Investigators-
dc.date2017-08-17T20:26:59Z-
dc.date2017-08-17T20:26:59Z-
dc.date2013-03-
dc.date2017-08-17T17:59:20Z-
dc.date.accessioned2019-04-29T15:45:04Z-
dc.date.available2019-04-29T15:45:04Z-
dc.date.issued2013-03-
dc.identifierMcMurray, John J. V.; Anand, Inder S.; Diaz, Rafael; Maggioni, Aldo P.; O'Connor, Christopher; et al.; Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF); Wiley; European Journal of Heart Failure; 15; 3; 3-2013; 334-341-
dc.identifier1388-9842-
dc.identifierhttp://hdl.handle.net/11336/22625-
dc.identifier1879-0844-
dc.identifierCONICET Digital-
dc.identifierCONICET-
dc.identifier.urihttp://rodna.bn.gov.ar:8080/jspui/handle/bnmm/301075-
dc.descriptionAIMS: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes. METHODS AND RESULTS: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate < 60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106-117) g/L. CONCLUSION: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.-
dc.descriptionFil: McMurray, John J. V.. University of Glasgow; Reino Unido-
dc.descriptionFil: Anand, Inder S.. University of Minnesota; Estados Unidos-
dc.descriptionFil: Diaz, Rafael. Estudios Clínicos Latinoamérica; Argentina-
dc.descriptionFil: Maggioni, Aldo P.. Associazione Nazionale Medici Cardiologi Ospedalieri; Italia-
dc.descriptionFil: O'Connor, Christopher. University of Duke; Estados Unidos-
dc.descriptionFil: Pfeffer, Marc A.. Brigham and Women’s Hospita; Estados Unidos-
dc.descriptionFil: Solomon, Scott D.. Brigham and Women’s Hospital; Estados Unidos-
dc.descriptionFil: Tendera, Micha. Medical University of Silesia; Polonia-
dc.descriptionFil: van Veldhuisen, Dirk J.. University of Groningen; Países Bajos-
dc.descriptionFil: Moetaz, Albizem. Amgen Inc.; Estados Unidos-
dc.descriptionFil: Cheng, Sunfa. Amgen Inc.; Estados Unidos-
dc.descriptionFil: Scarlata, Debra. Amgen Inc.; Estados Unidos-
dc.descriptionFil: Swedberg, Karl. University of Gothenburg; Suecia-
dc.descriptionFil: Young, James B.. Cleveland Clinic. Endocrinology and Metabolism Institute; Estados Unidos-
dc.descriptionFil: Toblli, Jorge Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.descriptionFil: RED-HF Committees Investigators.-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.languageeng-
dc.publisherWiley-
dc.relationinfo:eu-repo/semantics/altIdentifier/url/http://onlinelibrary.wiley.com/doi/10.1093/eurjhf/hfs204/abstract-
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1093/eurjhf/hfs204-
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576902/-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/-
dc.sourcereponame:CONICET Digital (CONICET)-
dc.sourceinstname:Consejo Nacional de Investigaciones Científicas y Técnicas-
dc.sourceinstacron:CONICET-
dc.source.urihttp://hdl.handle.net/11336/22625-
dc.subjectHeart failure-
dc.subjectAnaemia-
dc.subjectÉtica Médica-
dc.subjectCiencias de la Salud-
dc.subjectCIENCIAS MÉDICAS Y DE LA SALUD-
dc.titleBaseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.typeinfo:ar-repo/semantics/articulo-
Aparece en las colecciones: CONICET

Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Mostrar el registro sencillo del ítem